Unicycive Therapeutics, Inc. (UNCY)

Over the past six months, Unicycive's stock has been impacted by several events. In June 2025, the FDA issued a Complete Response Letter for OLC, which likely negatively impacted the stock. In August 2025, the company announced its second-quarter financial results and requested a Type A meeting with the FDA. In September 2025, the company held a Type A meeting with the FDA to discuss the resolution of the CRL. In November 2025, the company announced its third-quarter financial results and presented new analysis of OLC data. In December 2025, Unicycive resubmitted its NDA to the FDA for OLC, which experienced a moderate negative market reaction. In January 2026, the FDA accepted the resubmitted NDA for OLC, setting a target action date, which likely had a positive impact. In February 2026, the company is scheduled to participate in Guggenheim's Emerging Outlook: Biotech Summit, and the stock price gained 8.08% on February 6, 2026.

The provided information does not indicate any specific demand seasonality for Unicycive Therapeutics, Inc.'s products and services.

Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for kidney diseases, operating within the Health Technology sector. Its lead product candidates include Renazorb (OLC), a phosphate binding agent for hyperphosphatemia in CKD patients on dialysis, UNI-494, an investigational treatment for acute kidney injury, and UNI-220.

Unicycive Therapeutics, Inc. is based in Los Altos, California, and focuses on developing and commercializing therapies for kidney diseases in the United States.

Unicycive Therapeutics generally holds a positive reputation among analysts, with a consensus rating of "Moderate Buy" and a significant forecasted upside. The FDA's Complete Response Letter in June 2025 could have negatively impacted the company's reputation, but the subsequent proactive engagement with the FDA, the resubmission of the NDA in December 2025, and the FDA's acceptance of the resubmission in January 2026 demonstrate the company's commitment to resolving regulatory hurdles. The positive clinical data for OLC also contributes to a favorable perception of the company's product development capabilities.

Approximately 26.66% of Unicycive's stock is owned by institutional investors, 21.10% by insiders, 2.84% by public companies and individual investors, and 49.40% by retail investors. Major institutional owners include Vivo Capital, LLC, Octagon Capital Advisors LP, and Nantahala Capital Management, LLC. Shalabh K. Gupta, the CEO, owns the most shares among individual investors.